Heterologous Sequential mRNA Vaccination of Indian Rhesus Macaques Elicits Broad Binding and Neutralizing Antibody

Thomas B Voigt1,2, Noor Ghosh1, Brandon C Rosen1,3

  • 1Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

Viruses
|May 27, 2026
PubMed

Insights

New mRNA vaccines show promise for broad protection against deadly Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV). Sequential vaccination in macaques generated robust antibody responses, paving the way for effective countermeasures against future HNV outbreaks.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Henipaviruses (HNVs), such as Nipah virus (NiV) and Hendra virus (HeV), are highly pathogenic zoonotic viruses lacking approved human vaccines.
  • Emerging divergent HNVs like Ghana virus (GhV), Langya virus (LayV), and Mojiang virus (MojV) necessitate broadly protective vaccine strategies.

Purpose of the Study:

  • To evaluate antibody responses to sequential mRNA vaccines encoding the attachment glycoprotein (gG) of NiV, GhV, and/or LayV in Indian rhesus macaques.
  • To assess the breadth and functionality of antibody responses against diverse HNVs.

Main Methods:

  • Pilot study involving sequential mRNA vaccination in rhesus macaques.
  • Quantification of serum binding antibody responses via ELISA against five HNV gG antigens.
  • Assessment of functional activity through neutralization assays with pseudoviruses and receptor-blocking ELISA.

Main Results:

  • Sequential vaccination induced high-titer, broad IgG binding responses against all five tested HNV gGs.
  • Pan-genus vaccine regimens elicited moderate neutralizing antibody titers against NiV, HeV, and GhV.
  • Specific regimens demonstrated potent but narrow neutralization (NiV-only) or robust GhV neutralization with limited cross-reactivity (GhV-LayV-GhV).

Conclusions:

  • mRNA vaccination can elicit broadly reactive binding and neutralizing antibodies across divergent HNVs.
  • This study provides the first evidence of GhV pseudovirus neutralization.
  • Findings support the development of next-generation pan-genus HNV vaccines to mitigate future outbreaks.